Myocardial interleukin-6 in the setting of left ventricular mechanical assistance: relation with outcome and C-reactive protein

Caruso, Raffaele; Caselli, Chiara; Cozzi, Lorena; Campolo, Jonica; Viglione, Federica; Parolini, Marina; Nonini, Sandra; Trunfio, Salvatore; D'Amico, Andrea; Pelosi, Gualtiero; Giannessi, Daniela; Marraccini, Paolo; Frigerio, Maria; Parodi, Oberdan

doi:10.1515/cclm-2014-0633

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, patients receiving a centrifugal flow cfLVAD were operated on earlier in their disease process, preventing a stage with sliding on inotropes or even worse. Moreover, it was reported that preoperative IL-6 and CRP levels were higher in INTERMACS I patients scheduled for cfLVAD implantation, suggesting that patients with end-stage heart failure classified in a lower class of INTERMACS score (e.g., INTERMACS I or II) probably have a more pronounced disbalance in inflammatory biomarkers preoperatively with a probable worse outcome, such as vasoplegia and related early post-cfLVAD implantation complications, such as right ventricular failure and kidney failure [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

FLAVOUR Study: FLow profiles And postoperative VasOplegia after continUous-flow left ventriculaR assist device implantation

Kersten,

Numan,

van der Schoot

et al. 2024

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

This study aims to associate the incidence of postoperative vasoplegia and short-term survival to the implantation of various left ventricular assist devices differing in hemocompatibility and flow profiles. The overall incidence of vasoplegia was 25.3% (73/289 patients) and 30.3% (37/122), 25.0% (18/72), and 18.9% (18/95) in the axial flow (AXF), centrifugal flow (CF), and centrifugal flow with artificial pulse (CFAP) group, respectively. Vasoplegia was associated with longer intensive care (ICU) and hospital length of stay (LOS) and mortality. ICU and in-hospital LOS and 1-year mortality were the lowest in the CFAP group. Post hoc analysis resulted in a p-value of 0.43 between AXF and CF; 0.35 between CF and CFAP; and 0.06 between AXF and CFAP. Although there is a trend in diminished incidence of vasoplegia, pooled logistic regression using flow profile and variables that remained after feature selection showed that flow profile was not an independent predictor for postoperative vasoplegia. Graphical Abstract

show abstract

Section: Discussionmentioning

confidence: 99%

FLAVOUR Study: FLow profiles And postoperative VasOplegia after continUous-flow left ventriculaR assist device implantation

Kersten,

Numan,

van der Schoot

et al. 2024

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

show abstract

Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts

Nascimbene,

Bark,

Smadja

2024

Blood

View full text Add to dashboard Cite

Over the past two decades, there has been a significant increase in the utilization of long-term mechanical circulatory support (MCS) for the treatment of cardiac failure. Left ventricular assist devices (LVADs) and total artificial hearts (TAHs) have been developed in parallel to serve as bridge-to-transplant and destination therapy solutions. Despite the distinct hemodynamic characteristics introduced by LVADs and TAHs, a comparative evaluation of these devices regarding potential complications in supported patients has not been undertaken. Such a study could provide valuable insights into the complications associated with these devices. Although MCS has shown substantial clinical benefits, significant complications related to hemocompatibility persist, including thrombosis, recurrent bleeding, and cerebrovascular accidents. This review focuses on the current understanding of hemostasis, specifically thrombotic and bleeding complications, and explores the influence of different shear stress regimens in long-term MCS. Furthermore, the role of endothelial cells in protecting against hemocompatibility-related complications of MCS is discussed. We also compare the diverse mechanisms contributing to the occurrence of hemocompatibility-related complications in currently used LVADs and TAHs. By applying the existing knowledge, we present, for the first time, a comprehensive comparison between long-term MCS options.

show abstract

Interleukin-6 and cardiac operations

Yuan¹

2018

European Cytokine Network

View full text Add to dashboard Cite

Myocardial interleukin-6 in the setting of left ventricular mechanical assistance: relation with outcome and C-reactive protein

Abstract: Cardiac IL-6 levels do not contribute to improve risk profile of LVAD recipients in relation to clinical inpatient post-implantation. Instead, plasma IL-6 and serum CRP concentrations are more effective in predicting the severity of the clinical course in the early phase of LVAD therapy.

Cited by 3 publications

References 24 publications

FLAVOUR Study: FLow profiles And postoperative VasOplegia after continUous-flow left ventriculaR assist device implantation

FLAVOUR Study: FLow profiles And postoperative VasOplegia after continUous-flow left ventriculaR assist device implantation

Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts

Interleukin-6 and cardiac operations

Contact Info

Product

Resources

About